Survival rate and risk factors www.selleckchem.com/products/MK-2206.html of death were studied by using Kaplan-Meier curves and Cox proportional hazards models. Results: 68 pts without hepatocellular carcinoma (HCC) with a first episode of DC: ascites (n=28), gastrointestinal bleeding (n=3), jaundice (n=6), combined episode (including spontaneous bacterial peritonitis, hepato-renal syndrome and hepatic encephalopathy, n=31), were included in 32 centers between 2009 and 2013 (72% males, median age: 48 [IQR Interquartile Range 45-52] yrs, median follow-up: 18.6 months [9.2 - 35.3]). At inclusion, median HIV and HCV viral loads were 565 [100-3200] copies/mL and 5.8 [5.1–6.2] logIU/mL, respectively. Thirty-three pts (49%)

were infected by genotype 1. The median CD4 cell count was 301 [176-465] cells/mm3. Child-Pugh score was A in 24%, B in 47% and C in 29%. The median MELD and MELDNa scores were 13.27 [10.61 - 16.3] and 16.54 [12.17-19.46], respectively. The CDC stage was GS-1101 research buy A in 32%, B in 16% and C in 52% pts. The median number of episodes of DC was 2 [1-3] during follow-up. Overall survival

rate was 69%, 53% and 43% at 1, 2 and 3 yrs, respectively. In multivariate analysis, baseline MELD score was a significant predictor of mortality, adjusted for age, HIV viral load, albumin level and CD4 cell count: adjusted Hazards Ratio HR for an increase of 3 units of 1.12 [95% Confidence Interval CI: [1.18–1.64], p<0.0001. Other multi-variate models considering either MELDNa (for an increase of 3 units) or Child score (C versus A), found adjusted HR of 1.53 [1.27-1.85]; p<0.0001 and 5.2 [1.4–20.0]; p=0.02, respectively. According to the three classes of MELD score: [6-11], [12-15] and ≥ 16, the survival 上海皓元医药股份有限公司 rate at 1yr was 84%, 83%, 48%, respectively (class ≥ 16 vs <16: p=0.0007). The kinetic MELD scores from enrollment significantly differed between alive and deceased pts (+0.02 and +0.25/months, respectively; p<0.0001). Conclusion: Classical criteria CHILD-Pugh, MELD and MELDNa

are adapted to the HIV/HCV coinfected patients with end stage liver disease. The kinetic of MELD score represent also an accurate criterion to help guide decisions on referral for transplant evaluation. Disclosures: Hélène Fontaine – Independent Contractor: gilead, BMS, MSD, Roche, Janssen Isabelle Poizot-Martin – Board Membership: Janssen, MSD, Bristol Myers Squibb, ABBOTT; Consulting: ViiV Healthcare Karine Lacombe – Advisory Committees or Review Panels: Janssen, MSD, Gilead Philippe Morlat – Board Membership: GILEAD; Consulting: ViiV health Care Georges-Philippe Pageaux – Advisory Committees or Review Panels: Roche, Roche, Roche, Roche; Board Membership: Astellas, Astellas, Astellas, Astellas The following people have nothing to disclose: Moana Gelu-Simeon, Tatiana Bayan, Maria Ostos, Elina Teicher, Pierre Tattevin, Stephanie Dominguez, David Zucman, Julie Chas, Pascal P.